Company news

Sophiris Bio Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights

November 12, 2013

Sophiris Bio Applies for Voluntary Delisting from TSX

November 5, 2013

Sophiris Announces First Patients Dosed in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

October 28, 2013

Sophiris Bio to Present at the Stifel Healthcare Conference

September 5, 2013

Sophiris Bio Closes $65 Million Public Offering

August 23, 2013

Sophiris Bio Prices its Previously Announced Public Offering of Common Shares

August 16, 2013

Sophiris Bio Announces Share Consolidation

August 12, 2013

Sophiris Bio Reports Second Quarter Financial Results and Recent Key Operational Highlights

August 5, 2013

Sophiris Bio Announces an Addition to its Board of Directors

July 15, 2013

Sophiris Bio Announces Changes to Board of Directors

July 12, 2013

Sophiris Bio Inc. Announces Election of Directors

June 14, 2013

Sophiris Bio Reports First Quarter Financial Results and Recent Key Operational Highlights

April 30, 2013

Correction - Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ

February 18, 2013

Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ

February 15, 2013

Sophiris Bio Reports Fourth Quarter and Year-End 2012 Financial Results and Key Operational Highlights

February 13, 2013

Sophiris Bio Appoints a New Director to the Board

November 30, 2012

Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights

November 12, 2012

Sophiris Bio to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

November 6, 2012

Sophiris Bio Announces 12 Month Follow-Up Data from Phase 2b TRIUMPH Clinical Trial of PRX302 in Patients with Benign Prostatic Hyperplasia

October 9, 2012

Sophiris Bio to Present at the 11th Annual BIO Investor Forum

October 2, 2012

Sophiris Bio Announces Resignation of Alexander Casdin

September 14, 2012

Sophiris' Drug for Benign Prostatic Hyperplasia was Well Tolerated Using the Preferred Transrectal Route of Administration

August 31, 2012

Forty Year Industry Veteran Randall E. Woods Named CEO at Sophiris Bio

August 16, 2012

Sophiris Bio Reports Second Quarter Financial Results

August 13, 2012

Sophiris Bio Reports First Quarter Financial Results and Achievements

May 14, 2012

Protox Therapeutics Changes Name to Sophiris Bio

April 2, 2012